[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,453,751
  • Shares Outstanding, K 68,533
  • Annual Sales, $ 189,760 K
  • Annual Income, $ -196,540 K
  • EBIT $ -192 M
  • EBITDA $ -191 M
  • 60-Month Beta 1.94
  • Price/Sales 34.75
  • Price/Cash Flow N/A
  • Price/Book 53.66

Options Overview Details

View History
  • Implied Volatility 82.94% (+9.86%)
  • Historical Volatility 53.72%
  • IV Percentile 90%
  • IV Rank 60.94%
  • IV High 112.19% on 07/08/25
  • IV Low 37.30% on 05/16/25
  • Expected Move (DTE 5) 3.83 (4.06%)
  • Put/Call Vol Ratio 1.20
  • Today's Volume 22
  • Volume Avg (30-Day) 196
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 3,056
  • Open Int (30-Day) 3,098
  • Expected Range 90.35 to 98.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.83
  • Number of Estimates 6
  • High Estimate $-0.78
  • Low Estimate $-0.94
  • Prior Year $-0.75
  • Growth Rate Est. (year over year) -10.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
79.40 +18.60%
on 05/01/26
99.00 -4.88%
on 05/05/26
+8.69 (+10.17%)
since 04/08/26
3-Month
74.50 +26.40%
on 03/30/26
106.30 -11.41%
on 02/09/26
-9.44 (-9.11%)
since 02/06/26
52-Week
55.31 +70.26%
on 05/14/25
122.20 -22.94%
on 12/11/25
+33.45 (+55.09%)
since 05/08/25

Most Recent Stories

More News
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference

BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 94.17 (-2.14%)
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

-- IMCIVREE ® (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following FDA approval on March 19, 2026...

RYTM : 94.17 (-2.14%)
Will Rhythm Pharmaceuticals Finally Explain How It Plans to Keep Growing Beyond the Obvious?

Barchart Research What to Expect from RYTM Earnings RYTM Generated May 4, 2026 Current Price $85.58 EPS Estimate $$-0.86 Consensus Rating Strong Buy Average Move 4.34% Will Rhythm Pharmaceuticals Finally...

RYTM : 94.17 (-2.14%)
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society

-- Pediatric patients (n=10) with acquired hypothalamic obesity achieved sustained reductions in BMI and BMI-Z at 2.5 years of setmelanotide therapy -- -- Weight category improvements observed in pediatric...

RYTM : 94.17 (-2.14%)
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity

-- First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity -- -- European Commission grants authorization in adults and children 4 years of age and above with acquired...

RYTM : 94.17 (-2.14%)
Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026

BOSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...

RYTM : 94.17 (-2.14%)
Rhythm Pharmaceuticals Announces Changes to Board of Directors

-- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical...

RYTM : 94.17 (-2.14%)
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

-- European Commission decision anticipated in second quarter of 2026 -- BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical...

RYTM : 94.17 (-2.14%)
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)

PITTSBURGH , March 20, 2026 /PRNewswire/ -- PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, announced that it...

RYTM : 94.17 (-2.14%)
Stocks Fall on Spillover Effects from Iran War

The S&P 500 Index ($SPX ) (SPY ) today is down -0.88%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.59%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.22%. March E-mini S&P futures...

GOOGL : 400.80 (+0.71%)
AMAT : 435.44 (+6.04%)
AAPL : 293.32 (+2.05%)
SNDK : 1,562.34 (+16.60%)
DHI : 147.63 (+1.14%)
BLDR : 77.40 (-2.53%)
$IUXX : 29,234.99 (+2.35%)
ASML : 1,592.02 (+4.97%)
FIGS : 11.63 (-24.33%)
ZNM26 : 110-240s (+0.21%)
MSFT : 415.12 (-1.34%)
KBH : 49.52 (+0.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide,...

See More

Key Turning Points

3rd Resistance Point 99.72
2nd Resistance Point 98.24
1st Resistance Point 96.21
Last Price 94.17
1st Support Level 92.69
2nd Support Level 91.20
3rd Support Level 89.17

See More

52-Week High 122.20
Fibonacci 61.8% 96.65
Last Price 94.17
Fibonacci 50% 88.75
Fibonacci 38.2% 80.86
52-Week Low 55.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.